Drugs / Delpacibart Zotadirsen
Delpacibart Zotadirsen
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05670730 | Nov 2022 → Nov 2024 | Duchenne muscular dystrophy | Avidity Biosciences, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06244082 | Jan 2024 → Apr 2027 expected | Duchenne muscular dystrophy | Avidity Biosciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07587242 | Jun 2026 → May 2029 expected | Duchenne muscular dystrophy, atrophic muscular disease | Avidity Biosciences, Inc. | Not yet recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07250737 | — | Duchenne muscular dystrophy, X-linked disease, atrophic muscular disease | Avidity Biosciences, Inc. | Available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Delpacibart Zotadirsen | “A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping” NCT07587242 ↗ |
| Known as | AOC 1044 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05670730 ↗ |
| Known as | Delpacibart 44dmd01 conjugate | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068231 ↗ |
| Route | Intravenous | “AOC 1044 will be administered via intravenous (IV) infusion” NCT05670730 ↗ |